Text Size

CARE - Quality Improvement in Cardiovascular Secondary Prevention in Primary Care, Through Delegation of Consultations to the Nurse.

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00713960
First received: July 10, 2008
Last updated: January 13, 2012
Last verified: January 2012
History of Changes
  Purpose

Quality Improvement in Primary Care: delegation of check-ups to nurses in general practice


Condition
Cardiovascular Disease

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: CARE - Quality Development in Cardiovascular Disease in General Practice

Resource links provided by NLM:

MedlinePlus related topics: Cholesterol
U.S. FDA Resources

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Cholesterol, HDL -cholesterol, LDL-Cholesterol, Blood pressure, Exercise, Waist-circumference, BMI, Smoking status, fasting plasma-glucose, medication taken [ Time Frame: As needed, min. baseline and after 6 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Number of visits pr. patients, drop-out [ Time Frame: Annually ] [ Designated as safety issue: No ]

Enrollment: 2193
Study Start Date: April 2008
Study Completion Date: December 2010
Primary Completion Date: December 2010 (Final data collection date for primary outcome measure)
Groups/Cohorts
1
Patients in secondary prevention of cardiovascular disease in primary care

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Primary care clinic

Criteria

Inclusion Criteria:

  • Patients in secondary prevention of cardiopathy (ischaemic heart disease, claudication intermittence, thrombotic apoplexy cerebri, diabetes) who are not followed in an outpatient department.

Exclusion Criteria:

  • Patients who suffer from diabetic nephropathy will be excluded
  • According to the general practitioners appraisal, patients who suffer from severe co morbidity can be excluded as well.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00713960

  Show 66 Study Locations
Sponsors and Collaborators
AstraZeneca
Investigators
Study Chair: Henrik Ommen, MD Lægerne i Løgumkloster I/S, Denmark
Study Chair: Dorte Knudsen Lægerne Sønderåparken, Denmark
  More Information

No publications provided

Responsible Party: AstraZeneca
ClinicalTrials.gov Identifier: NCT00713960     History of Changes
Other Study ID Numbers: NIS-CDK-DUM-2008/1
Study First Received: July 10, 2008
Last Updated: January 13, 2012
Health Authority: Denmark: Danish Dataprotection Agency

Keywords provided by AstraZeneca:
Quality development project
primary care nurses
cardiovascular disease
secondary prevention
follow-up

Additional relevant MeSH terms:
Cardiovascular Diseases

ClinicalTrials.gov processed this record on May 19, 2013